This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McCormick Gears Up for Q3 Earnings Release: Things to Keep in Mind
by Zacks Equity Research
MKC's strong momentum and effective growth strategies might be overshadowed by rising expenses, soft volume trends and currency risks in its Q3 performance.
Procter & Gamble Stock Up 21% YTD: Should You Stay Invested or Exit?
by Rajani Lohia
PG's strong global presence and cost-saving strategies offer promise. However, challenges in key markets and ongoing geopolitical tensions pose risks.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Clorox Stock Hits 52-Week High: Is it Time to Buy, Hold or Sell?
by Zacks Equity Research
CLX looks poised for growth through recent recovery, improved distribution channels, and focus on innovation and expansion, amid inflation and cost headwinds.
How Will the Sale of Better Health VMS Business Aid CLX Stock?
by Zacks Equity Research
Clorox completes the divestiture of its Better Health VMS business. The company's IGNITE strategy also bodes well.
Take the Zacks Approach to Beat the Markets: Philip Morris, IAMGOLD, Solventum in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Take the Zacks Approach to Beat the Markets: Vista Gold, TransMedics, Accenture in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Procter & Gamble (PG) Trades Near 52-Week High: Should You Buy?
by Rajani Lohia
Procter & Gamble (PG) witnesses consistent growth, with the stock creating new 52-week highs in less than two months.
Here's Why Clorox (CLX) is a Strong Momentum Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Clorox (CLX) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Clorox (CLX) Q4 Earnings Beat Estimates, Gross Margin Expands
by Zacks Equity Research
Clorox's (CLX) fiscal 2025 gross margin is expected to improve by around 100 basis points, driven by comprehensive margin management efforts.
Clorox (CLX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Clorox (CLX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Clorox (CLX) Tops Q4 Earnings Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 18.18% and 3.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Clorox (CLX) Raises Dividend: What it Means for Investors
by Zacks Equity Research
Clorox's (CLX) strategy of incremental dividend growth not only bolsters shareholder income but also reinforces investor confidence in the company.
Here's Why Clorox (CLX) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insights Into Clorox (CLX) Q4: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Clorox (CLX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Factors to Watch Before TreeHouse Foods' (THS) Q2 Earnings
by Zacks Equity Research
TreeHouse Foods' (THS) Q2 results are likely to reflect challenges such as the restart of the broth facility, along with the lag in pricing adjustments to counter cocoa inflation.
Kellanova (K) Q2 Earnings Coming Up: Key Factors to Consider
by Zacks Equity Research
Kellanova's (K) second-quarter performance is likely to reflect the impacts of elevated inflation rates and industry-wide elasticities. Unfavorable foreign currency rates pose a threat.
Tyson Foods (TSN) Q3 Earnings in the Cards: Things to Note
by Zacks Equity Research
Tyson Foods (TSN) Q3 performance will likely reflect gains from growing protein demand. However, a tight cattle supply environment might have been a spoilsport.
Procter & Gamble (PG) Q4 Earnings Top Estimates
by Zacks Equity Research
P&G (PG) delivered earnings and revenue surprises of 2.19% and 0.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Awaits for Pilgrim's Pride's (PPC) Q2 Earnings Release?
by Zacks Equity Research
Pilgrim's Pride's (PPC) Q2 performance will reflect gains from robust market momentum and improved efficiency. However, an elevated cost environment is a hurdle.
Service Corporation (SCI) Q2 Earnings Coming Up: Factors to Note
by Zacks Equity Research
Service Corporation's (SCI) second-quarter 2024 performance will likely reflect gains from strength in the Cemetery segment. However, a rising interest rate environment poses a threat.
Can AB InBev (BUD) Deliver Q2 Earnings Beat Despite High Costs?
by Zacks Equity Research
AB InBev's (BUD) Q2 results are expected to reflect strong demand for its brand portfolio, pricing actions, premiumization and revenue management initiatives, offset by higher costs.
Can Clorox's (CLX) Pricing & Cost-Saving Plan Aid Q4 Earnings?
by Zacks Equity Research
Clorox's (CLX) Q4 results are expected to reflect gains from pricing strategies and cost-saving initiatives, as well as progress on the IGNITE strategy, amid high SG&A expenses.
Hershey's (HSY) Q2 Earnings in the Cards: Key Things to Note
by Zacks Equity Research
Hershey's (HSY) Q2 results are likely to reflect gains from brand strength, but high commodity costs, increased selling, marketing and administrative expenses and currency volatility are concerns.